Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 328Lung Neoplasms 158Pancreatic Neoplasms 30Adenocarcinoma of Lung 27Colorectal Neoplasms 26Neoplasms 24Small Cell Lung Carcinoma 21Breast Neoplasms 17Neoplasm Metastasis 15Mesothelioma, Malignant 14Ovarian Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Mesothelioma 10Stomach Neoplasms 9Colonic Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Sarcoma 7Prostatic Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Melanoma 6Lymphoma, Non-Hodgkin 6Esophageal Neoplasms 6Lymphoma 5Thoracic Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4

Interventions

Carboplatin 2sintilimab 1pembrolizumab 1HLX07 1Gemcitabine 1Cisplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous NSCLC × Gemcitabine × Thoracic × Clear all
NCT03629925 2023-02-28

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
357 enrolled 14 charts
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡